Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Patent
1995-06-07
2000-05-02
Johnson, Nancy A.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
4241901, 42419711, 4242361, 4242401, 4242771, 514 2, 530350, A61K 3512, A61K 3566, A61K 3910
Patent
active
060569603
ABSTRACT:
Compositions characterized by ADP-ribosyltransferase activity are useful in promoting prophylactic and/or therapeutic responses as are promoted by, e.g., pertussis toxin but directed against another target antigen (e.g., a cancer-related antigen) in a mammalian patient.
REFERENCES:
patent: 4372945 (1983-02-01), Likhita
McCall, C. A., et al., "Biotherapy: A new dimension in cancer treatment", Bio/technology, 7:231 (1989).
Minagawa, H., et al., "Endogenous tumor necrosis factor induction with Bordetella pertussis vaccine as a triggering agent and its therapeutic effect on MM46 carcinoma-bearing mice.", Jpn. J. Cancer Res., 79:384 (1988).
Minagawa, H., et al., "Intraumoral Induction of tumour necrosis factor by systemic administration of Bordetella pertussis vaccine", Br. J. Cancer 62:372 (1990).
Munoz, J. J., "Action of pertussigen (pertussis toxin) on the host immune system", in Pathogeneals and Immunity In Pertussis (Wardlaw, A. C., & Parton, R., Eds.) Chapter 8, pp. 173-192, John Wiley & Sons Ltd., New York (1988).
Ohnishi, M., et al., "Characterization of Immunological activity of a low toxicity antitumor lipoploysaccharid from Bordetella pertussis", Microbiol. Immunol., 38;733 (1994).
Ohnishi, M., et al., "Anti-tumour activity of low-toxicity lipoplysaccharide of Bordetlla pertussis", Br. J. Cancer 69, 1036 (1994).
Pizza et al, (1989) Science vol. 246, 497-500 Mutants of Pertussis Toxic Suitable for Vaccine Development.
Black et al. (1988) Science vol. 240, 656-659 ADP-ribsyltransferase Activity of Pertussis Toxin . . .
Nencioni et al. (1990) Injection & Immunity, vol. 58, 1308-1315 Characterization of Genetically Inactivated Pertussis Toxin . . .
Dranoff et al. (1993) Proc. Natl. Acad Sci. USA, vol. 90, 3539-3543 Vaccination with Activated Tumor Cells . . .
Konishi, Yoichi et al: "Possible model of liver carcinogenesis using inhibitors of NAD+ADP ribosyl transferase in rats" Toxicol. Pathol., vol. 14, No. 4, 1986, pp. 483-488, XP002087054 *the whole document*.
Ashton, Anthony C. et al: "ADP-ribosylationof cerebrocortical synaptosomal proteins by cholera, pertussis and botulinum toxins" Toxicon, vol. 28, No. 8, 1990, pp. 963-973, XP002087055 *the whole document*.
Weiss, A.A. and Hewlett, E.L. (1986) Virulence factors of Bordetella pertussis. Annu. Rev. Microbiol. 40:661-686.
Mitchell, M., Kan-Mitchell, J., Kempf, R. Harel, W., Shau, H. and Lind, S. (1988) Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 48:5883-5893.
Marsili, I., Pizza, M., Giovannoni, F., Volpini, G., Bartalini, M., Olivieri, R., Rappuoli, R. and Nencioni, L. (1992) Cellular pertrussis vaccine containing a Bordetella pertussis strain that produces a nontoxic pertussis toxin molecule. Infect. Immun. 60: 1150-1155.
Greco, D., Salmaso, S., Mastrantonio, P., Giuliano, M., Tozzi, A.E., Anemona, A., degli Atti, M.L.C., Giammanco, A., Panei, P., Blackweldeer, W.C., Klein, D.L., Wassilak, S.G.F. and Group, P.P.W. (1996) A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N. Engl. J. Med. 334: 341-348.
LandOfFree
Compositions exhibiting ADP-ribosyltransferase activity and meth does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions exhibiting ADP-ribosyltransferase activity and meth, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions exhibiting ADP-ribosyltransferase activity and meth will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1592005